Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer

Research and Reports in Urology

Volumn 8, Issue , 2016, Pages 21-25

  Takeuchi, Takumi ^a   Okuno, Yumiko ^a   Hattori Kato, Mami ^a   Zaitsu, Masayoshi ^a   Mikami, Koji ^a  

^a KANTO ROSAI HOSPITAL   (Japan)

Author keywords

AR V7; Castration resistant; Prostate cancer

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; COMPLEMENTARY DNA; ENZALUTAMIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

EID: 84975774983     PISSN: None     EISSN: 22532447     Source Type: Journal    
DOI: 10.2147/RRU.S98877     Document Type: Article

References (13)

1. Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg. 1942;115(6):1192-1200.
2. Matsuda A, Matsuda T, Shibata A, et al. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2014;44(4):388-396.
3. Vital Statistics Japan. Ministry of Health, Labour and Welfare.
4. Fizazi K, Scher H, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-992.
5. Ryan C, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-148.
6. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
7. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-433.
8. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69(1):16-22.
9. Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate. 2011;71(15):1656-1667.
10. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028-1038.
11. BioGPS. [webpage on the Internet]. Androgen Receptor. Available from: http://biogps.org/#goto=genereport&id=367. Accessed December 22, 2015.
12. Akasaka E, Nakano H, Satojin K, et al. The interaction of photoprotective effects between keratinocytes and melanocytes via endothelin-1/stem cell factor signaling. Hirosaki Med J. 2011;62(2-4):138-143.
13. Yates DR, Rouprêt M, Drouin SJ, et al. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy. Prostate. 2012;72(12):1382-1388.